Biogen will acquire San Diego's RayThera for up to $1B, expanding its immunology pipeline with early-stage anti-inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results